"The upcoming development no longer poses any difficulty; it's just a matter of time."
Professor Li Hongwei remarked with a bit of sentiment. Having done research for so many years, this was the first time he encountered such a smooth development of a new material. He couldn't deny that it felt good.
"Xiao Zhao, once the siRNA colloidal bundle is developed, we will share the patent together."
After a pause, Li Hongwei seemed to have made some kind of decision and said.
This siRNA colloidal bundle, after all, is a cutting-edge nanomaterial, and it can also serve as a drug carrier with immense potential in medical and clinical applications.
If one were to estimate its value, it would be in the billions, of course, that's the buyout price. Even if the patent isn't sold, the annual patent licensing and usage fees would still be in the tens of millions.
Sharing between the two means a revenue of tens of millions each year.
